Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and ...

Danish pharmaceutical group Novo Nordisk is preparing to launch an ICC arbitration worth US$830 million against a Singapore ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

Aviva Investors has flagged three of its funds as failing to deliver value for customers, though said no changes will be made ...

Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Malgré les reculs politiques, de nombreuses grandes entreprises européennes publient déjà leurs reportings CSRD.